Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aspen vs Transcarent

Aspen
Graded #373

Higher grade

vs+3.1999999999999957
Transcarent
Graded #445

Lower grade

The verdict

Aspen takes it — 58.4/100 to 55.2/100.

Aspen grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aspen (Aspen Health Systems LLC) is a LegitScript-certified telehealth clinic offering compounded semaglutide and tirzepatide as physician-chosen weekly injections, with flat pricing at every dose.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTranscarent +18
27
45
Dose & formulationAspen +24
64
40
Clinical oversightAspen +5
80
75
Labs & monitoringTranscarent +9
52
61
FulfillmentAspen +32
94
62
Contract termsTranscarent +8
47
55
Aspen · left barTranscarent · right bar

The numbers

MetricAspenTranscarent
WeighScore58.4/10055.2/100
GradeCC
Scorecard rank#373#445
Semaglutide$279/mo (3-month plan, compounded)Not disclosed
Tirzepatide$399/mo (compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Aspen

Graded #373 · C

Strengths

  • LegitScript-certified with an independently verifiable seal (#50306023) and HIPAA compliance — a strong trust signal for a compounded-GLP-1 telehealth
  • Names its dispensing pharmacy: Red Rock Compounding Pharmacy, LegitScript-certified and NABP-accredited, licensed in 49 states plus DC
  • Flat pricing at every dose ("same price at every dose, no surprises") plus free expedited shipping, so your cost won't rise as you titrate up
  • Competitive prepay rates — compounded semaglutide as low as $179/mo (12-mo) and tirzepatide $299/mo — with zero interest and no credit check
  • Money-back guarantee for qualifying patients who complete the full 28-week program without losing weight; available in all 50 states + DC

Where it loses points

  • Compounded semaglutide and tirzepatide only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
  • Even the "monthly" plan requires a 3-month commitment with three months of medication shipped and billed upfront — limited month-to-month flexibility
  • Standing month-to-month pricing is steep ($279 semaglutide, $399 tirzepatide); the lowest rates require 6- or 12-month prepay
  • The provider chooses semaglutide vs tirzepatide for you, so you can't freely pick your own molecule
  • Registered as Aspen Health Systems LLC at a Sheridan, WY address; async model with no routine video visit
Transcarent

Graded #445 · C

Strengths

  • Comprehensive Weight Health pathway from lifestyle to GLP-1s to surgery
  • Care team of doctors, nurses and pharmacists supports medication use
  • Uses direct pharma contracts and a transparent PBM to cut costs
  • Integrates bariatric surgery navigation alongside medication
  • Built on 15 years of Surgery Center of Excellence experience

Where it loses points

  • Distributed only via employers and health plans, no direct cash-pay
  • GLP-1 access depends on whether the plan covers the medication
  • No public individual monthly pricing
  • Not available to consumers without an eligible employer or plan

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard